Medicamen Organics Limited
Book Built Issue IPO · NSE
- Price band
- ₹32 - ₹34
- Lot size
- 4,000 shares
- Issue amount
- ₹10.54 cr
- Total subscription
- 965.49×
- Opens
- 21 Jun 2024
- Closes
- 25 Jun 2024
- Allotment
- 26 Jun 2024
- Listing
- 28 Jun 2024
Offer at a glance
Issue overview
- Issue size
- 31,00,000 shares
- Face value
- ₹10 Per Equity Share
- Minimum investment
- ₹1,28,000
- Fresh issue
- ₹10.54 cr
- Offer for sale
- ₹0 cr
- Registrar
- Kfin Technologies Limited
- Listing exchange
- NSE
- Maximum investment
- ₹1,36,000
- Issue type
- Book Built Issue IPO
- Shares before issue
- 86,00,000
- Shares after issue
- 1,17,00,000
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 4,000 | ₹1,36,000 |
| HNI | 2 | 8,000 | ₹2,72,000 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| — | — |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 1.99 | 343.58 |
| RETAIL | 3.5 | 4,388.34 |
Financial performance
Company financials
in ₹ Lakhs · Reported periods may include interim results.
Key performance indicators
| Metric | Sep-23 | Mar-23 | Mar-22 |
|---|---|---|---|
| EPS | 1.89 | 1.6 | 0.15 |
| ROE | 0 | 0 | 0 |
| ROCE | 9.21 | 9.71 | 4.09 |
| RONW | 10.93 | 11.25 | 1.22 |
| PRE IPO(PE) | 30.53 | 0 | 0 |
| POST IPO(PE) | 15.41 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Medicamen Organics Limited, founded in 1995, is a trusted pharmaceutical company specializing in the development, manufacturing, and distribution of a wide range of pharmaceutical dosages, including tablets, capsules, syrups, ointments, gels, and dry powders. Catering to both government and private sectors as a contract manufacturer, the company offers 84 products across various therapeutic categories, such as antibacterials, antifungals, antidiabetics, antihypertensives, and multivitamin preparations. Medicamen Organics has a strong domestic presence and exports to multiple international markets, including Africa, CIS, and Southeast Asia. The company operates two WHO-GMP-approved manufacturing facilities in Haridwar, Uttarakhand, spanning 21,536 square feet. With partnerships with 38 domestic contract manufacturers and 12 merchant exporters, the company employed 116 people as of September 30, 2023, ensuring high-quality production and global reach.
Strengths
- Strong Leadership: Medicamen Organics Limited is led by experienced promoters and a skilled management team, ensuring strategic growth and effective decision-making.
- Trusted Customer Relationships: The company has built long-standing relationships with its customers, driving consistent demand and business stability.
- Efficient Operations: A highly capable operational team ensures high productivity and quality manufacturing, reinforcing the company’s reliability in the pharmaceutical industry.
Risk factors
- Regulatory Challenges: The company needs multiple approvals and licenses to operate. Any delays or failures in obtaining them could impact business activities.
- Raw Material Cost Fluctuations: Price changes in raw materials can increase production costs and affect profitability.
- Customer Dependence: Relying on a few major customers means losing one could significantly impact revenue and overall financial stability.
Promoters
Mr. Bal Kishan Gupta
Registrar & documents
Lead manager
GYR Capital Advisors Private Limited
Registrar & contacts
Kfin Technologies Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
10 Community Centre,, No 2 Ashok Vihar Phase II, New Delhi, Delhi, 110052
+91-9818222845
[email protected]Company website ↗Understanding MEDIORG IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.